Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2024 | The role of the hematologist and cardiologist in treating patients with amyloidosis

Ronald Witteles • 27 May 2024
ISA 2024
Amyloidosis Rare Diseases

Ronald Witteles, MD, Stanford University, Stanford, CA, shares his thoughts on the importance of close collaboration between cardiologists and hematologists when treating patients with light chain (AL) amyloidosis, and further explains the value of collaboration across other multidisciplinary teams (MDTs). This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting for Pfizer, Alnylam, BridgeBio, Novo Nordisk, Astra Zeneca, Janssen, Alexion

More from Ronald Witteles

The current state of cardiac transplantation for AL and ATTR amyloidosis
3:15
The current state of cardiac transplantation for AL and ATTR amyloidosis
Ronald Witteles • 27 May 2024
What key challenges remain in the diagnosis of ATTR amyloidosis?
4:11
What key challenges remain in the diagnosis of ATTR amyloidosis?
Ronald Witteles • 27 May 2024

Related Videos

Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
4:17
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
Maria Teresa Voso • 12 Jun 2026
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
Advances in the clinical understanding of advanced SM and educational gaps that remain
1:17
Advances in the clinical understanding of advanced SM and educational gaps that remain
Deepti Radia • 12 Jun 2026
Updates with bezuclastinib in non-advanced and advanced systemic mastocytosis: SUMMIT & APEX trials
2:41
Updates with bezuclastinib in non-advanced and advanced systemic mastocytosis: SUMMIT & APEX trials
Deepti Radia • 12 Jun 2026
The content of VJHemOnc is intended for healthcare professionals